Studies such as those discussed herein highlight the importance of CAR-T-mediated targeting of FRβ in solid tumors, such as ovarian cancer, as well as myeloid-derived malignancies; however, clinical validation of these findings could shed more light on the suitability of FRβ as a cancer immunotherapy target antigen (91). The gene discussed is FOLR2; the disease is ovarian cancer.